🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Erin M. Bertino

The Ohio State University Wexner Medical Center

ORCID: 0000-0003-3174-0928

Also affiliated with The Ohio State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.104Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

Cancer Investigation(2025)10.1080/07357907.2025.2557004
Top 78%
0.104DataRank
Top 78%1 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +15 more

Papers

Driven by 11 papers — median percentile 11. Top paper: “Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)”.

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084
N/A
0.574DataRank · unranked
45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

Cancer Immunology Immunotherapy(2020)10.1007/s00262-020-02674-w
N/A
0.571DataRank · unranked
44 citations

Daniel Spakowicz, Songzhu Zhao, Sandip H. Patel, Andrew Johns, Madison Grogan +11 more

Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer

Investigational New Drugs(2025)10.1007/s10637-025-01591-y
N/A
0.165DataRank · unranked
2 citations

Ruohan Wu, Lai Wei, Mikhail M. Dikov, Shankar Suman, Po‐Lan Su +17 more

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

Cancer Investigation(2025)10.1080/07357907.2025.2557004
Top 78%
0.104DataRank
Top 78%1 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +15 more

Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy

Clinical Lung Cancer(2022)10.1016/j.cllc.2021.12.010
N/A
0DataRank · unranked
44 citations

Lai Wei, Sandip H. Patel, Gabrielle Lopez, Madison Grogan, Mingjia Li +17 more

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

Journal of Cancer Research and Clinical Oncology(2022)10.1007/s00432-022-04340-3
N/A
0DataRank · unranked
40 citations

Gabriel Tinoco, Songzhu Zhao, Lai Wei, Andrew Johns, Sandip Pravin Patel +14 more

Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03392-9
N/A
0DataRank · unranked
11 citations

Songzhu Zhao, Gabrielle Lopez, Austin Secor, Parthib Das, Nitya Surya +19 more

Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy

Lung Cancer(2025)10.1016/j.lungcan.2025.108832
N/A
0DataRank · unranked
0 citations

Mingjia Li, Songzhu Zhao, Lai Wei, Evelyn Goodyear, Kevin Ho +16 more

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-03068-2
N/A
0DataRank · unranked
47 citations

Songzhu Zhao, Mingjia Li, Sandip H. Patel, Andrew Johns, Madison Grogan +13 more

Bone modifying agents and skeletal related events in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e18593
N/A
0DataRank · unranked
0 citations

Songzhu Zhao, Lai Wei, Abdul Miah, Mingjia Li, Gabrielle Lopez +11 more

Early changes in lymphocyte/monocyte ratio on-treatment as a prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitors

Research Square(2021)10.21203/rs.3.rs-758097/v1
Top 100%
0DataRank
Top 100%0 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +14 more